Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29022643 | 1.00 | ESR2 (0.56) | ESR2CA1CA2CA7CA9 | |
| SCHEMBL28090962 | 0.91 | ESR2 (0.48) | ESR2CA1CA2CA7CA9 | |
| SCHEMBL28429576 | 0.88 | ESR2 (0.45) | ESR2CA1CA2CA7CA9 | |
| Water SCHEMBL27525432 | 0.84 | — | — | |
| SCHEMBL2370 | 0.84 | — | — | |
| SCHEMBL6733562 | 0.84 | CA1 (0.79) | ESR2CA1CA2CA7CA9 | |
| SCHEMBL197522 | 0.84 | CA1 (0.79) | ESR2CA1CA2CA7CA9 | |
| SCHEMBL9151672 | 0.84 | CA1 (0.79) | ESR2CA1CA2CA7CA9 | |
| SCHEMBL21314698 | 0.81 | — | — | |
| SCHEMBL21831895 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 750 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117623838-A | Chiral sulfoxide ester compound and preparation method thereof | 贵州大学 | 2024-03-01 | — | — | CN | claimed |
| CN-117304175-A | Preparation method of chiral 3-benzofuran-3-amino-2-oxindole derivative | 浙江理工大学 | 2023-12-29 | — | — | CN | claimed |
| CN-115926175-A | Halogen-free polyphosphate flame retardant with high polymerization degree and preparation method thereof | 缔久高科技材料(南通)有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-115385956-A | Biaryl diphosphine ligands and transition metal complexes thereof | 东莞市均成高新材料有限公司 | 2022-11-25 | — | — | CN | claimed |
| CN-114805012-A | Synthesis method of allylic trifluoromethyl compound | 陇东学院 | 2022-07-29 | — | — | CN | claimed |
| US-20210292281-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | REATA PHARMACEUTICALS, INC. (US) | 2021-09-23 | — | — | US | claimed |
| CN-113271924-A | Aqueous composition, in particular for the treatment of mucous membranes and/or wounds | B.布劳恩梅尔松根股份公司 | 2021-08-17 | — | — | CN | claimed |
| EP-2320954-B1 | DIAGNOSTIC AGENTS SELECTIVE AGAINST METALLOPROTEASES | BRACCO IMAGING SPA (IT) | 2019-09-04 | — | — | EP | claimed |
| CN-105272888-B | Double aryl alkene alkane acid compounds and its production and use | 中国科学院上海药物研究所 | 2018-03-27 | — | — | CN | claimed |
| WO-2017078927-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-05-11 | — | — | WO | claimed |
| US-20020132134-A1 | Electroluminescent (EL) devices | XEROX CORPORATION | 2002-09-19 | — | — | US | claimed |
| US-20020115864-A1 | Potentiators of glutamate receptor function | ARNOLD MACKLIN BRIAN (US) | 2002-08-22 | — | — | US | claimed |
| EP-1212300-A1 | AZACYCLOALKANONE SERINE PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | claimed |
| US-6358981-B1 | FOR THERAPY OF CENTRAL NERVOUS SYSTEM (CNS) DISORDERS | ELI LILLY AND COMPANY | 2002-03-19 | — | — | US | claimed |
| EP-1178959-A1 | ALPHA-AMINO-BETA-SULFONYL HYDROXAMIC ACID COMPOUNDS | G.D. SEARLE & CO. (US) | 2002-02-13 | — | — | EP | claimed |
| WO-2001019795-A1 | AZACYCLOALKANONE SERINE PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | claimed |
| WO-2000071514-A1 | α-AMINO-β-SULFONYL HYDROXAMIC ACID COMPOUNDS | G.D. SEARLE & CO. (US) | 2000-11-30 | — | — | WO | claimed |
| CN-1259948-A | 6,7-disubstituted-4-aminopyrido [2,3-D] pyrimidine compounds | ABBOTT LAB (US) | 2000-07-12 | — | — | CN | claimed |
| EP-0980864-A2 | Sulphonamide derivatives | ELI LILLY AND COMPANY (US) | 2000-02-23 | — | — | EP | claimed |
| WO-2000006157-A1 | SULPHONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115864-A1 | Potentiators of glutamate receptor function | GRM2, GRIN1, GRM1 | ESR2 598/4885CA1 1016/4885CA2 734/4885 |
| US-20210292281-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | RORC, RORB, RORA | ESR2 694/4885CA1 1833/4885CA2 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.